Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (SHA:688796)
China · Delayed Price · Currency is CNY 70.96
-1.87 (-2.57%)
At close: Feb 6, 2026
SHA:688796 Revenue
Biocytogen Pharmaceuticals (Beijing) had revenue of 620.96M CNY in the half year ending June 30, 2025, with 89.99% growth. This brings the company's revenue in the last twelve months to 1.19B, up 48.76% year-over-year. In the year 2024, Biocytogen Pharmaceuticals (Beijing) had annual revenue of 980.45M with 36.76% growth.
Revenue (ttm)
1.19B
Revenue Growth
+48.76%
P/S Ratio
23.97
Revenue / Employee
911.88K
Employees
1,306
Market Cap
28.54B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 980.45M | 263.54M | 36.76% |
| Dec 31, 2023 | 716.91M | 183.03M | 34.28% |
| Dec 31, 2022 | 533.88M | 179.33M | 50.58% |
| Dec 31, 2021 | 354.56M | 101.01M | 39.84% |
| Dec 31, 2020 | 253.54M | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Hang Zhou Iron & Steel | 60.93B |
| Sinoma International Engineering Co.,Ltd | 47.39B |
| Far East Smarter Energy | 28.08B |
| Hla Group Corp. | 21.30B |
| Jiangsu Yangnong Chemical | 11.58B |
| Zhejiang Dingli Machinery Co.,Ltd | 8.34B |
| KEBODA TECHNOLOGY | 6.67B |
| Tianjin Pharmaceutical Da Ren Tang Group Corporation | 5.37B |